Cancer research
Investigators at the Guangzhou Medical University in China have published a new study evaluating the efficacy and safety of two combination treatments for hepatocellular carcinoma (HCC). The researchers analyzed the outcomes of 459 HCC patients who underwent either transarterial chemoembolization (TACE) with hepatic arterial infusion chemotherapy (HAIC) combined with molecular
Cancer treatment
Researchers at the First Affiliated Hospital of Sun Yat-sen University in Guangzhou, People's Republic of China, have made significant discoveries in the field of liver cancer treatment. The study, published in Liver Cancer, aimed to evaluate the outcomes of patients with initially unresectable hepatocellular carcinoma (HCC) who received
Cancer treatment
Scientists at the University of South China have made a groundbreaking discovery in the field of oncology, identifying a promising novel HSP90AB1 inhibitor for hepatocellular carcinoma (HCC) treatment. According to their research, published in the journal Molecular Diversity, the compound 4'-O-methylochnaflavone has shown potential in inhibiting the proliferation
Cancer treatment
Research conducted by Wuhan University has led to a significant breakthrough in the treatment of liver cancer, a major global health burden. According to the study, a novel nanocomposite material, b-glucan nanotubes loaded with BFP-FeSe nanocomposites, has been developed to enhance photothermal and photodynamic therapy (PTT/PDT) treatment for hepatocellular
Hepatocellular carcinoma
Researchers at the First Affiliated Hospital of Sun Yat-sen University in Guangzhou, People's Republic of China, have made significant discoveries in the field of liver cancer treatment. The study, published in Liver Cancer, aimed to evaluate the outcomes of patients with initially unresectable hepatocellular carcinoma (HCC) who received
Cancer treatment
Research conducted by Wuhan University has led to a significant breakthrough in the treatment of liver cancer, a major global health burden. According to the study, a novel nanocomposite material, b-glucan nanotubes loaded with BFP-FeSe nanocomposites, has been developed to enhance photothermal and photodynamic therapy (PTT/PDT) treatment for hepatocellular
Cancer research
Researchers from the First Affiliated Hospital of Anhui Medical University have developed a novel NLR-based prognostic model that effectively stratifies hepatocellular carcinoma (HCC) patients by survival risk. This study aimed to evaluate the prognostic value and biological function of NLR genes in HCC. The researchers analyzed transcriptomic and clinical data
Cancer research
Scientists at the University of South China have made a groundbreaking discovery in the field of oncology, identifying a promising novel HSP90AB1 inhibitor for hepatocellular carcinoma (HCC) treatment. According to their research, published in the journal Molecular Diversity, the compound 4'-O-methylochnaflavone has shown potential in inhibiting the proliferation
Cancer research
Researchers at the First Affiliated Hospital of Sun Yat-sen University in Guangzhou, People's Republic of China, have made significant discoveries in the field of liver cancer treatment. The study, published in Liver Cancer, aimed to evaluate the outcomes of patients with initially unresectable hepatocellular carcinoma (HCC) who received
Cancer research
Researchers at Tongji University in Shanghai, People's Republic of China, have discovered a crucial mechanism driving hepatocellular carcinoma (HCC) bone metastasis, characterized by poor prognosis and severe skeletal complications. The study identifies the HMGB1/LCN2/JAK1/STAT3 axis as the central mechanism driving HCC bone metastasis through tumor-osteoclast
Cancer research
A multicenter study conducted at Teine Keijinkai Hospital in Sapporo, Japan, has identified a modified tumor marker score that can help predict treatment outcomes for patients with unresectable hepatocellular carcinoma (HCC). The study, published in the journal Liver Cancer, found that the score, which incorporates alpha-fetoprotein (AFP) and des-gamma-carboxy prothrombin
Cancer research
Investigators at McMaster University have discovered a potential new treatment for hepatocellular carcinoma (HCC) by combining lenvatinib, a multi-tyrosine kinase inhibitor, with salsalate, a rheumatoid arthritis therapy. The research team found that the combination of these two treatments significantly improved the efficacy of lenvatinib in MASH-driven HCC. The study, published
